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5Unidad de Genómica, Fundación Parque Cientı́fico de Madrid, Madrid, Spain
6Aragon Institute for Health Research (IIS Aragón), Obstetrics Department, Hospital Clı́nico Universitario Zaragoza, Spain
7Aragon Institute for Health Research (IIS Aragón), Microbiology Department, Hospital Clı́nico Universitario Zaragoza, Spain
8Red de Salud Materno Infantil y del Desarrollo (SAMID), RETICS, Instituto de Salud Carlos III (ISCIII), Subdirección General de
Evaluación y Fomento de la Investigación, Fondo Europeo de Desarrollo Regional (FEDER), Spain
*Author for correspondence: Tel.: +34 976 715 412; +34 672 022 215; jonas@araid.es
Aim: The aim of this study was to determine if alterations in DNA methylation in the human placenta
would support suspected preterm labor as a pathologic insult associated with diminished placental health.
Methods: We evaluated placental DNA methylation at seven loci differentially methylated in placental
pathologies using targeted bisulfite sequencing, in placentas associated with preterm labor (term birth
after suspected preterm labor [n = 15] and preterm birth [n = 15]), and controls (n = 15). Results: DNA
methylation levels at the NCAM1 and PLAGL1 loci in placentas associated with preterm labor did differ
significantly (p < 0.05) from controls. Discussion: Specific alterations in methylation patterns indicative
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The mammalian placenta orchestrates efficient exchange of nutrients, waste and gas between mother and fetus
and contributes to the fetal environment through its endocrine functions [1]. Placental dysfunction underlies
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pregnancy complications such as preeclampsia, gestational hypertension, small-for-gestational-age infants and
spontaneous preterm birth. An imbalance of pro- and anti-angiogenic growth factors and deficient uteroplacental
vascularization, as well as placental inflammation [2–4], represent pathological conditions that are common to the
majority of pregnancy-related syndromes including preterm labor.
Preterm labor (PTL) is defined by increased uterine contractility with intact membranes requiring hospitalization
and follow-up at <37 weeks of gestation, and affects 10–24% of pregnancies [5]. It is a frequent cause for hospital
admission, and therefore of economical and practical relevance. PTL is deemed to be the common outcome
of a variety of pathologies including infections, disruption of maternal–fetal tolerance, premature trophoblastic
or decidual senescence, inflammation and a decline in progesterone action [5,6]. Not all cases of PTL end in
preterm birth (PT). Spontaneously, or after acute intravenous tocolysis, actually in about 50% of cases birth
occurs normally at term (≥37 weeks weeks). These latter cases are referred to as suspected preterm labor (SPL).
While historically SPL has been considered neutral for posterior health, evidence is accumulating that risks are
associated with SPL [7]. These include a higher incidence mall-for-gestational-age neonates compared with those
born at term [8], increased frequency of neurodevelopmental and behavioral problems at preschool age [9], as well as
retarded neurodevelopment [10]. In the latter study, no significant differences were found in any cognitive domain
between children who were born late preterm and children who were born at term after suspected PTL (TBSPL).
In most human tissues, the vast majority of the genome is highly methylated (>70%) [11,12]. DNA methy-
lation is among the epigenetic mechanisms that control gene expression and regulation, both during embryonic
development [13,14] and in human pathologies [15,16]. Alterations in DNA methylation have been documented in
human pathologies including human cancer [17,18] and placental pathologies that lead to reduced infant growth rate,
pre-eclampsia and preterm delivery (PT) [19–21]. A continued examination of the relationship between epigenetic
alterations in the placenta and placental physiopathology, developmental programming of the fetus and postnatal
health will help clinical practice in the long-term.
In this manuscript, we analyzed DNA methylation, to determine whether alterations in human placenta may
be used to compare SPL (resulting in either term [TB] or preterm [PT] births) with normal births. A variety of
studies [22] has addressed alterations in the epigenome associated with PT and labor, invariably examining maternal
or fetal tissues as opposed to placental tissue [23,24]. We are interested in placental pathologies, and placental
epigenetic markers for PTL have not been defined so far. Therefore, we selected a set of loci whose methylation
levels are reportedly altered in placental pathologies, in the hope of describing alterations specific to PTL as
opposed to PT. In particular, we selected inflammation-related loci whose placental methylation levels are altered
in preeclampsia (NCAM1 and TNF or TNFA) [25,26] or under conditions associated with placental stress such as
low oxygen conditions (CFB and ZNF217) [25]. Both the FLT1 [27] and VEGFA genes were included based on the
importance of angiogenesis in placental pathologies [3,5]. Genomic Imprinting describes the determination of gene
dosis (and ultimately expression levels) based on parental-origin-specific methylation patterns [28,29]. As a group,
mammalian imprinted genes play an important role in the placenta by regulating fetal and placental growth and
development [30,31], and deregulation of a variety of imprinted genes contributes to placental pathologies. The
imprinted gene PLAGL1 encodes a paternally expressed transcription factor (also called Zac1 in the mouse and
LOT1 in human) that binds to target genes through zinc-finger domains [32,33]. As altered placental expression of
PLAGL1 has been directly implicated in IUGR (Intrauterine growth restriction) [34], this locus was included in our
analysis. We have used bisulfite-genomic DNA sequencing to compare methylation patterns at these selected loci
between term born, PT and term birth after suspected PTL.
Materials & methods
Ethics statement
The local ethics committee (CEICA) approved the study protocol (CP – CI PI13/0162 08/01/2014), and parents
provided written informed consent (protocolo y información para el paciente v2 de 29/12/2013).
Placental DNA samples & genomic loci analyzed
Samples analyzed represent a subset of a prospective cohort study of preterm (26–36 weeks) or term (≥37 weeks)
delivery pregnancies after suspected PTL. Suspected PTL was defined by uterine contractions, ultrasound cervical
length <25 mm in the presence of intact membranes. For more information we refer to the original description
of the cohort [35]. Subjects from each condition were selected at random from the original groups described in [35],
complying with two more requisites: we included the maximum number available of cases defined as ‘inflammation’
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in the hope of extracting useful data under these conditions, and we made sure that the average levels of expression
in the selected group were similar to those reported in the cohort [35].
Placental tissue was sampled from chorionic villus sites and stored in RNA™ later as described [35]. To extract
DNA, tissue was homogenized in 1 ml of genomic lysis buffer (30 mM Tris-HCl pH 8.5, 40% [m/v] guanidinium
chloride, 30 mM ethylenediaminetetraacetic acid [EDTA] pH 8), the resulting supernatant was incubated overnight
with 1 mAU protease (QIAGEN, Hilden, Germany) at 65◦C. Cell debris and other small particles were removed
by centrifugation at full speed for 2 min at room temperature (RT) and the homogenate was frozen at -80◦C until
further use. Genomic DNA was isolated by isopropanol precipitation according to standard protocols, re-suspended
in 100 μl of TE buffer (10 mM Tris-Cl pH 8, 1 mM EDTA pH 8) and stored at -80◦C. To extract DNA, tissue
was homogenized in 1 ml of genomic lysis buffer (30 mM Tris-HCl pH 8.5, 40% [m/v] guanidinium chloride,
30 mM EDTA pH 8) and, the resulting supernatant was incubated overnight with 1 mAU protease (QIAGEN)
at 65 oC. Cell debris and other small particles were removed by centrifugation at full speed for 2 min at RT and
the homogenate was frozen at -80oC until further use. Genomic DNA was isolated by isopropanol precipitation
according to standard protocols, resuspended in 100 μl of TE buffer (10 mM Tris-Cl pH 8, 1 mM EDTA pH 8)
and stored at -80oC. The amplicons analyzed for methylation levels have been previously described in the following
reports: FLT1 [36]; VEGFA [36]; ZNF217 [25]; PLAGL1 [37]; CFB [25]; NCAM1 [26]; TNF [26] (Gene nomenclature
as approved by HUGO Gene Nomenclature Committee [HGNC]). Amplicons were selected in the 150–250 bp
size range to facilitate posterior sequencing (see below). Genomic localization (Homo sapiens GRch 38.97), and
other details regarding the amplicons employed are listed in Table 2, each amplicon contained a range of 2–22
CpGs. The locus-specific sequences of primers are listed in Table 3.
Methylation analysis
Genomic DNA was bisulfite converted using the EZ DNA methylation kit (Zymo Research Corp., CA, USA)
following the manufacturer’s instructions. As a measure of successful conversion, overall percentages of non-CpG
methylation varied from 0.03 to 0.06 % among all loci and samples studied. Target regions (Table 2) were amplified
using tailed oligos that consist of a unique amplicon-specific part, fused to a 5′-tail comprising sequences necessary
for library preparation and sequencing reactions, and a 10 bp multiplex identifier (MID) to identify each sample.
Amplification products were purified from agarose gels, titrated, diluted, pooled, subjected to emulsion-PCR.
The resulting amplicon-specific libraries were subjected to Illumina sequencing in MiSeq (2 × 250 reads). The
sequencing run yielded over 840000 filtered, quality reads, an average of about 1800 reads per amplicon per
sample (range 500 to 5000). Bisulfite conversion, amplification of target sequences and sequencing were carried
out at Fundación Parque Cient́ıfico de Madrid (FPCM), c/Faraday 7, Madrid, Spain. Reads obtained were filtered
and sorted according to their MID and the reference sequence. Alignments and calculation of the percentage
methylation have subsequently been performed using the freely available software Bismark [38]. The percentage of
methylation per sample within each CpG was calculated as the percentage C/C+T, the mean value of all CpG
dinucleotides per amplicon was calculated to represent the methylation value of a particular locus.
Gene expression analysis
Tissue homogenisation, RNA extraction, reverse transcription (RT) and quantitative polymerase chain reaction
(qPCR) were carried out as described [35], on the same biopsies analyzed for DNA methylation (see above).
Primers for detection of PLAGL1 expression have been reported before [34]. TaqMan R© qPCR assays (Applied
Biosystems, CA, USA) used for all other markers are listed in Table 3. RPL19 and SDHA were used as reference
genes [34,39].
Expression suite (Thermo Fisher Scientific, MA, USA) was used to calculate Ct values with respect to the
average of the cycle threshold (Ct) values of the RPL19 and SDHA reference genes. Data were further recalculated
as 2-Ct, with respect to the mean Ct value of the samples in the control group as described [40]. The resulting
numbers are listed in the Figures and represent fold change in expression.
Statistical analysis
Normal distributions were assessed using Kolmogorov–Smirnov tests. Mann–Whitney or Student’s t-test was used
to compare cases and controls. Analysis of variance (ANOVA) or Kruskal Wallis tests were used to compare the
three groups. Chi-square or Fisher tests were used to analyse categorical variables. Post hoc Bonferroni tests were
applied to compare multiple groups. Data are presented as mean ± standard deviation (SD). Two-sided p-values
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To study potential epigenetic alterations associated with PTL, we analyzed in this study a subset of the 104 placentas
from the cohort of 132 patients examined in another study recently published by our group [35]. We included 15
from each group: PT, delivery at TBSPL and normal term delivery (control [con]). Groups were chosen with the
intention to both include a maximum number of cases with sterile inflammation (see below), and maintain median
expression levels of angiogenic factors similar to the original groups [35]. Maternal sociodemographic characteristics
and perinatal data are shown in Table 1. There were no significant differences among groups in the number of
smokers included, sex of the infants or maternal age. Preterm infants had significantly lower birth weights, earlier
gestational ages at delivery and, were admitted to the neonatal care unit at a significantly higher rate than term-born
infants. Moreover, significantly different from the normal term delivery group, women in PTL groups (both PT
birth and TB) had a lower maternal body mass index, a lower frequency of spontaneous labor and higher rates of
PT in previous pregnancies.
To study potential epigenetic alterations in the placenta associated with PTL, DNA methylation levels of selected
loci (Table 2) were compared between PT, TBSPL and Con groups. Candidate targets were selected based on
reports describing differential methylation in human placenta tissue associated with preeclampsia or placental
pathology-related processes (see Introduction). We applied massive parralel sequencing of PCR products amplified
from bisulfite-treated DNA to determine the DNA methylation status of the selected DNA regions. Representative
results for the PLAGL1, TNF and CFB loci are shown in Figure 1. Data for the four remaining loci can be viewed in
Supplementary Figure 1. While the mean methylation level per CpG varied across the loci, the mean methylation
level per CpG in each group (PT, TBSPL and Con) was remarkably consistent (higher in Con for PLAGL1; lower
in Con for CFB; only small changes in TNF) across the amplicons. Except for the FLT1 locus, no alterations were
detected in individual CpGs that were different from those calculated across amplicons.
Table 1. Maternal sociodemographic characteristics and perinatal data.
Preterm delivery (n = 15) Term delivery after suspected
preterm labor (n = 15)
Term delivery
control (n = 15)
p-value
Maternal age, mean (SD) 27.4 (6.1) 31.2 (6.5) 31.03 (4.7) 0.149
Maternal body mass index, kg/m2, mean (SD) 23.8 (4.3) 21.4 (2.6) 26.7 (4.5) 0.006
Nulliparity, n (%) 9 (60) 8 (53.3) 12 (80) 0.283
Caucasian, n (%) 10 (66.7) 15 (100) 12 (80) 0.340
Smokers, n (%) 1 (6.6) 1 (6.6) 3 (20) 0.429
Preeclampsia, n (%) 1 (6.7) 0 (0) 0 (0) 0.306
Infant sex, male, n (%) 7 (46.7) 11 (73.3) 8 (53.3) 0.306
Gestational age at birth, days, mean (SD) 243 (18.6) 276 (10.1) 275 (7.7) 0.001
Previous preterm delivery, n (%) 2 (13.3) 4 (26.7) 1 (6.6) 0.023
Birth weight, g, mean (SD) 2240 (482.3) 3167 (344.7) 3282 (398.0) 0.001
Cesarean section, n (%) 2 (13.3) 4 (26.7) 8 (53.3) 0.055
Labor†, n (%) 15 (100) 11 (73.3) 8 (53.3) 0.012
Cervical ripening‡, n (%) 0 (0.0) 4 (26.7) 3 (20) 0.111
Antenatal steroids, n (%) 5 (33.3) 12 (80) 0 (0.0) 0.001
Placental inflammation§, n (%) 5 (33.3) 3 (20) 0 (0.0) 0.056
Apgar at 5 min 7, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1
Neonatal care unit admission, n (%) 9 (60) 1 (6.7) 1 (6.7) 0.001
Umbilical artery pH 7.15, n (%) 0 (0.0) 1 (8.3) 0 (0.0) 0.675
†Spontaneous labor.
‡Prostaglandin E2.
§Placental expression level of both IL6 and TNFA 1.5 multiples of the median. Data were analysed using ANOVA (continuous variables) and either Fisher or
Chi-square tests (categorical variables).
ANOVA: Analysis of variance; SD: Standard deviation.
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Figure 1. Placental DNA methylation at consecutive CpG dinucleotides across the genomic regions analyzed for the
LOT1/PLAGL1, TNF and CBF loci as indicated. Mean DNA methylation at each CpG site in control samples (n = 15,
green), or samples defined by preterm labor and term born (TBSPL, n = 15, red) and born preterm (PT, n = 15, blue),
respectively. The percentage methylation is indicated on the vertical axis, consecutively numbered CpGs on the
horizontal axis.
Con: Control; PT: Preterm birth; TBSPL: Term birth after suspected preterm labor.
Table 2. Amplicons for methylation sequencing assays.
Target Chromosomal location Gene region Amplicon size Reference N◦ CpGs
VEGFA 6: 43769653 gene promoter 132 Kim et al., 2012 7
FLT1 13: 28495234 gene promoter 195 Kim et al., 2012 21
TNF 6: 31575675 promoter 001 transcript 177 Anton et al., 2014 6
CFB 6: 31945473 236 Yuen et al., 2013 3
NCAM1 11: 113276368 1 kb down-stream of
translation STOP codon
154 Anton et al., 2014 2
PLAGL1 6: 144007815 intron 1-2 177 Poole et al., 2013 22
ZNF217 20: 53583123 promoter 201 transcript 277 Yuen et al., 2013 5
Descriptions of amplicons produced for methylation sequencing assays, genomic localization is listed according to genome build Homo sapiens GRch 38.97.
Expression analysis:
Among the loci analyzed, methylation levels varied considerably (Table 4). In both normal placentas & in cases
of PTL, CpG sites across the FLT1 & VEGFA promoter regions were largely unmethylated (0–0.6 % methylation).
By contrast, methylation in the NCAM gene amounted to 89% (92–96% in the first CpG), indicating almost
complete methylation.
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Table 4. Altered methylation after suspected preterm labor.
PTL Controls p TBSPL PT Con p-value
n = 30 n = 15 n = 15 n = 15 n = 15
VEGFA 0.3 (0.3) 0.3 (0.3) 0.540 0.3 (0.3) 0.3 (0.3) 0.3 (0.3) 0.786
FLT1 0.4 (0.5) 0.4 (0.5) 0.538 0.4 (0.5) 0.4 (0.5) 0.4 (0.5) 0.601
TNF 8.3 (9.0) 8.8 (8.8) 0.547 9.0 (9.7) 7.6 (8.3) 8.8 (8.8) 0.326
CFB 27.5 (6.7) 24.4 (5.8) 0.051 27.2 (5.8) 27.7 (7.5) 24.4 (5.8) 0.259
NCAM1 83.8 (12.4) 86.9 (9.5) 0.009 82.0 (13.9) 85.5 (10.7) 86.9 (9.5) 0.001
PLAGL1 34.3 (8.1) 41.7 (9.3) 0.006 35.2 (7.1) 33.9 (9.0) 41.7 (9.3) 0.021
ZNF217 56.6 (25.0) 55.3 (21.0) 0.508 57.1 (25.3) 56.1 (24.9) 55.3 (21.0) 0.729
Placental DNA methylation of selected genes. DNA methylation (%) across the amplicons indicated in Table 2. Methylation values (mean +/− SD) for each locus in placental samples:
Left panel: from controls (n = 15) and combined preterm labor samples (PTL; n = 30).
†p-values have been calculated using Student’s t-test.
Right panel: from controls (n = 15), term birth after suspected preterm labor (n = 15), and preterm birth samples (n = 15).
‡p-values were calculated using one-way analysis of variance.
Con: Control; PT: Preterm birth; PTL: Combined preterm labor samples; SD: Standard deviation; TBSPL: Term birth after suspected preterm labor.
Differential placental DNA Methylation in PTL
Out of the genomic regions selected, several of the loci analyzed displayed differential DNA methylation in the
cases of PTL (PT and TBSPL combined) compared with controls (Table 4). Although we detected no differences
between the two groups in the TNF, FLT1, VEGF and ZNF217 genes, a trend toward higher methylation in the
CFB gene (p = 0.051), as well as significantly lower methylation in the NCAM1 and PLAGL1 loci was associated
with PTL (Table 4); p < 0.05 (Student’s t-test).
As the PTL group is a mixture of samples taken after either PT or term birth (TBSPL), the differences observed
may be the result of differences in gestational age. As the latter is a variable that cannot be adjusted or controlled
for in the PT group, we compared the three groups to identify alterations not limited to PT. Alterations in CFB,
NCAM1 and PLAGL1 methylation trended similarly in both the PT and TBSPL groups, compared with the term
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Figure 2. DNA methylation at CpG sites within the FLT1, VEGFA, TNF and CBF loci.
Placentas showing Inf (n = 8), all corresponding to the preterm labor group, are compared with NoI (n = 37), except for the CFB panel to
the top left, which compares control placentas (n = 15) to placentas from combined suspected PTL pregnancies (n = 30). Mean methylation
(%) values +/- SD at each locus were calculated across the region analyzed. Data were analyzed using using Student’s t-test.
Con: Control; Inf: Inflammation; Nol: Placentas without inflammation; PTL: Preterm labor; SD: Standard deviation.
delivery control group (Table 4, right panel). Statistical analysis showed significant differences among the three
groups in methylation levels at the NCAM1 and PLAGL1 loci (p = 0.001 and 0.021, respectively). To further
investigate differences between groups, we performed pair-wise comparisons. For several loci, no differences (p = 1)
were detected between the PT and TBSPL groups (CBF, PLAGL1, VEGF, ZNF217 and FLT1). Methylation at the
PLAGL1 locus was altered in both the PT and TBSPL groups compared with the term delivery control group,
although statistical significance was only reached for the PT vs. Con difference (see below). We conclude that at
several loci, alterations in placental DNA methylation trended similarly in both the PT and TBSPL group, and
therefore appear independent of gestational age.
Placental DNA methylation associated with Inflammation
Inflammation (in the absence of apparent infection) is a well-established cause of about 14% of PTL cases [41] and
can arbitrarily be defined by increased placental levels of both IL6 and TNFA [35]. We therefore assessed whether
inflammation was associated with altered DNA methylation (Supplementary Table 1). No differences were detected
for most loci including FLT1, PLAGL1, TNF and ZNF217 (Figure 2 & Figure 4B). Although sample size in the
inflammation group was small (n = 8), methylation at several loci was altered compared with the combined samples
without inflammation (n = 37). A slight (nonsignificant) increase was detected in the CFB lococ in the inflammation
group (Figure 2), in contrast to a significant increase in CFB methylation in the PTL group (Figure 2; panel CBF
Controls vs PTL). A marginally significant change in DNA methylation associated with inflammation was observed
in the FLT1 promoter (Figure 2). Apart from these trends, significant decreases in DNA methylation as a result of
inflammation occurred in the VEGFA (Figure 2) and NCAM1 loci (Figure 3).
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Figure 3. DNA methylation levels and mRNA expression levels of the NCAM1 gene in placental samples. Control
(n = 15) and combined preterm labor (PTL; n = 30) placentas were compared, as well as cases of Inf (n = 8) versus
placentas NoI (n = 37) and Con (n = 15), TBSPL (n = 15) and PT (n = 15). Top (A–C): Mean placental DNA methylation at
CpG sites downstream of the NCAM1 locus (see Table 1) was calculated based on average CpG methylation measured
by NGS of PCR products amplified from bisulfite-treated DNA. Data are shown as mean (+/- SD). Data were analyzed
using Student’s t-test (2 groups) or ANOVA (three groups). Bottom (D–F): mRNA levels were measured by qPCR using
RPL19 and SDHA as reference genes. Gene expression data are represented as mean value of each group +/- SD.
ANOVA: Analysis of variance; Con: Control; Inf: Inflammation; NGS: Next-generation sequencing; Nol: Placentas
without inflammation; PT: Preterm birth; PTL: Preterm labor; SD: Standard deviation; TBSPL: Term born after
suspected preterm labor.
Increased NCAM1 expression is associated placental inflammation
To establish the functional significance of the observed changes in DNA methylation, gene expression levels of
the NCAM1, CFB and PLAGL1 genes were analyzed using qRT-PCR in the 45 placentas under examination. At
the NCAM1 locus, we had detected significantly decreased levels of methylation associated with PTL (Figure 3A),
which was significantly associated with inflammation (Figure 3B) and rather specific for the PT group (Figure 3C,
p = 0.001). Pair-wise comparisons were performed to investigate differences in NCAM1 mRNA expression levels
between groups. No differences were observed between the PTL and control groups (Figure 3D). Moreover, in
contrast to the methylation levels, the expression level of NCAM1 was not significantly different between the PT,
TBSPL and Con groups (Figure 3F). However, increased NCAM1 mRNA expression was clearly associated with
inflammation (Inf ), as relative expression was 3.08 and 1.63 in Inf versus NoI, respectively (Figure 3E). We identify
epigenetic and transcriptional alterations in the NCAM1 locus in cases of inflammation-related PTL.
The association of PLAGL1 with PTL
We had detected significantly decreased methylation levels at the PLAGL1 locus associated with PTL (Figure 4A).
Decreased methylation was not restricted to the PT group, but was observed to a different degree in both PT and
TBSPL groups (Figure 4C). In agreement with the methylation data, expression of PLAGL1 mRNA was about 2.5-
fold increased in the combined PTL samples compared with controls (Figure 4D). Surprisingly, the PLAGL1 mRNA
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p = 0.63 p = 0.005
p = 0.127
Figure 4. Changes in methylation status are associated with altered mRNA expression of LOT1/PLAGL1. As Figure 3,
except for CpG sites within the first intron of the PLAGL1/LOT1 gene.
Con: Control; Inf: Inflammation; Nol: Placentas without inflammation; PT: Preterm birth; PTL: Preterm labor; TBSPL:
Term born after suspected preterm labor.
level was significantly higher in the inflammation (Inf ) group, compared with the samples without inflammation
(NoI), (relative expression was 89.39 and 35.68 in Inf vs NoI groups, respectively) (Figure 4E), as opposed to
unaltered methylation (Figure 4B). The latter observation suggests dual regulation of PLAGL1 mRNA levels by
inflammation-dependent and -independent mechanisms of PTL. Pair-wise comparisons to investigate differences
between groups (Figure 3F) showed that he expression levels of PLAGL1 trended toward an increase in both
PT and TBSPL groups, compared with the term delivery control group (p = 0.127 and 0.005, respectively). In
this preliminary study, decreased placental DNA methylation and increased mRNA expression of PLAGL1 was
associated with PTL.
Discussion
Altered methylation is associated with PTL
We studied genomic methylation in placental DNA obtained from cases of PTL. Candidate genes were selected
based on altered methylation in processes related to placental pathologies. The bisulfate-sequencing approach
employed yielded data of high confidence in terms of methylation levels at each individual CpG analyzed. We
found significant differences between cases of PTL and controls for methylation at the NCAM1 and PLAGL1 loci.
Comparing Con, PT and TBSPT groups, we found no differences whatsoever in the ZNF217 and VEGFA loci.
In contrast to a reported decrease in global DNA methylation levels in preterm deliveries [42], we describe a trend
toward increased methylation at the CFB locus (Table 4). At several loci, alterations in placental DNA methylation
trended similarly in both the PT and TBSPL group, and were not limited to the PT group. We therefore believe
these alterations are related to PTL and relatively independent of gestational age.
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It has been widely believed, that resolution of an episode of PTL has no secondary effects and does not cause
long-term effects for the fetus, neonate or infant if birth occurs at term [43]. The present data on methylation
patterns support an association between specific placental alterations and PTL. We postulate that the underlying
placental pathology may ultimately pose a short-term or future health risk. In combination of previous reports
on adverse effects on neurodevelopment [10] and placental gene expression [35], these results suggest that some of
the biological mechanisms underlying PTL similarly affect both preterm and term-born infants. Recently, large
scale studies have become available, which apply genome-wide technology to maternal or cord blood samples (and
tissues) in order to study potential biomarkers and predictors of PT [23,24,44]. However, such information is not yet
available for placenta. We hope that the potential epigenetic differences in the placenta related to PTL we describe
here may stimulate future efforts toward defining the placental epigenome and transcriptome of PTL.
Limitations of the study
Despite identifying changes that support the hypothesis that alterations may result from PTL independent of the
time of birth, the present study also has limitations. First and foremost, the sample size is small. The analysis
presented would certainly benefit from increased sample size, both with respect to PTL groups, as to the presence
of inflammation. Moreover, the potential influence of gender, maternal body mass index, labor and administration
of antenatal steroids on DNA methylation levels cannot be excluded. While TBSPL and control samples are
age-matched, by definition the PT samples are not. As a result, differences between PT and control samples may
be related to gestational age. Furthermore, at present we cannot exclude that altered DNA methylation levels
are a function of the proportion of different cell types present in the samples. As we tested methylation at loci
whose selection was based on alterations in placental pathologies different from PTL, our study was not directed at
identifying genes or loci that are directly involved in PTL. The differences in methylation presented in the NCAM1
and PLAGL1 genes are purely correlative as of now. Whether altered epigenetic and transcriptional control of these
genes underlie pregnancy complications and PTL remains to be established.
Our work provides a starting point for further analysis aimed at understanding both the causes of PTL and the
influence of PTL-associated changes on adverse intrauterine environment and posterior health.
Physiopathological implications of altered methylation
As disequilibrated immune responses are frequently postulated as primary initiators of the multiple subsequent
pathways leading to placental pathologies [45], we analyzed placental methylation at several loci encoding com-
ponents. No relationship was evident between methylation at the TNF locus and either PTL or inflammation.
Increased expression of TNFA in placental inflammation apparently is independent of methylation levels of the
TNF promoter. A significant increase in placental methylation was found in the CFB locus (Table 4), which in turn
was independent of inflammation (Supplementary Table 1). To the best of our knowledge, this is the first report
suggesting that the link between CFB and PTL merits further investigation.
Inflammation has been identified as a cause of about 14% of PTL cases [41,43]. It is therefore no surprise that
we found altered methylation that was strictly associated with inflammation, as was the case for the NCAM1
locus (Figures 2 & 3). In addition to a significant decrease in methylation in PTL (Figure 3A), both methylation
(Figure 3B) and expression (Figure 3E) of NCAM1 are significantly altered in case of inflammation. Moreover,
as expected, decreased methylation corresponds with increased expression, suggesting functional significance. As
NCAM1/CD56+ expression is not normally detected in trophoblasts [46], we suggest the signals may correspond to
either resident fetal macrophages (i.e., Hofbauer cells) [47], or infiltrating maternal cells, in other words, macrophages
or natural killer (NK) cells. Infiltration of macrophages in the trophoblast layer has been reported in a case of
spontaneous abortion [48].
In line with the importance of defective angiogenesis to placental pathologies including PT [5], we studied
VEGFA and FLT1 promoter methylation. We report low and PTL-independent overall methylation levels at both
the VEGFA and FLT1 loci similar to a previous report in the latter case [27]. In the context of the extremely low
level of VEGFA promoter methylation, a significant alteration in a small subset of cells may be relevant and drive
altered expression levels.
PLAGL1 methylation is very similar between both PTL groups (Figure 4) and (significantly) lower in both PTL
groups compared with normal births. In addition to altered methylation, increased PLAGL1 expression levels are
also associated with PTL (Table 4; Figure 4D). Methylation of this locus is lower in both PTL groups compared
with controls. While altered methylation of PLAGL1 has been previously associated with imprinting disorders [49]
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and preeclampsia [34], we describe here for the first time its association with PTL. Moreover, altered methylation
is accompanied with increased gene expression of this locus (Figure 4D–E). In mouse models, PLAGL1 has been
described to play a central role in regulation of a network of imprinted genes, both in embryos [32] and in a
neuroblastoma cell line [33]. The network controls cell cycle exit [33] and endocrine lineages [31]. Whether alterations
in these pathways and functions may also affect placental cell types and contribute directly or indirectly to PTL
remains to be established.
Conclusion
Based on the determination of DNA methylation levels at selected loci using targeted bisulfite sequencing, we
analyzed differences between PTL and controls. DNA methylation levels of the NCAM1 and PLAGL1 loci in
placentas associated with PTL did differ significantly from controls. In placentas with inflammation, methylation
levels were significantly altered at the NCAM1 locus. The alterations associated with PTL we describe may be
indicative of placental pathology associated with PTL, which is independent of the time of birth (term or preterm).
Future perspective
PTL is deemed to be the common outcome of a variety of pathologies including infections, disruption of maternal–
fetal tolerance and premature senescence . PTL may end in PT. However, in about 50% of cases birth occurs
normally at term (≥37 weeks). These latter cases are referred to as SPL. While historically SPL has been considered
neutral for posterior health, evidence is accumulating that risks are associated with SPL. Our results support the
hypothesis that specific placental alterations are associated with PTL, independent of the time of birth. We predict
that further research will underscore the relevance of PTL as a risk factor per se for placental health and short and
long-term health risk of the fetus.
Recently, genome-wide technology has been applied to maternal or cord blood samples (and tissues) in order
to study potential biomarkers and predictors of PT [23,24,44]. However, such information is not yet available for
placenta, and even less in the context of PTL and PT. We suggest the importance of obtaining this information,
to better understand placental pathologies. The potential epigenetic differences in the placenta related to PTL we
describe here may stimulate future efforts toward defining the placental epigenome and transcriptome of PTL.
An increasing number of data support a significant impact of placental methylation on placental and fetal heath.
Misexpression of imprinted genes in placenta has clearly hinted toward a correlation with abnormal birthweight of
infants [50], which in turn has been associated (both as undergrowth and as overgrowth) with metabolic as well as
cognitive disorders [51]. However, the direct relationship between altered methylation and future health impact is
still largely unknown and should be further investigated.
Summary points
• Placental methylation at the NCAM1, CFB and PLAGL1 loci in preterm labor (PTL) did differ significantly from
controls.
• Altered placental DNA methylation at the NCAM1 and VEGFA loci in PTL is associated with inflammation.
• Alterations in placental DNA methylation of selected loci appear associated with PTL per se, and independent of
gestational age at birth.
• In a small cohort, altered levels of both placental DNA methylation and mRNA expression of PLAGL1 appeared
associated with PTL.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at:
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